

Alliqua, Inc.  
Form 8-K  
April 23, 2014

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported): April 23, 2014

**Alliqua, Inc.**

(Exact Name of Registrant as Specified in its Charter)

Florida	001-36278	58-2349413
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2150 Cabot Boulevard West	19047
Langhorne, Pennsylvania	
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (215) 702-8550

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On April 23, 2014, Alliqua, Inc. (the “Company”) issued a press release announcing the launch of its Biovance human amniotic membrane allograft product at the Spring 2014 Symposium on Advanced Wound Care to be held at Gaylord Palms Hotel and Convention Center in Orlando, Florida from April 23 to April 27, 2014. A copy of the Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d)Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated April 23, 2014

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALLIQUA, INC.**

Dated: April 23, 2014 By: /s/ Brian Posner

Name: Brian Posner

Title: Chief Financial Officer